Application of C-32 triterpenoid cycloneoliitol in preparation of medicine for preventing or treating osteoporosis
By using C-32 triterpene cycloneolitsol as the active ingredient of the drug, the adverse reactions of Western medicine and insufficient development of traditional Chinese medicine in the treatment of postmenopausal osteoporosis were solved, and the effect of promoting osteoblast proliferation and improving bone density was achieved, which significantly improved the The therapeutic effect.
Patent Information
- Application Number
- CN202411099658.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art lacks effective drugs in the treatment of osteoporosis, especially postmenopausal osteoporosis. The long-term use of Western medicine brings adverse reactions, and traditional Chinese medicine has potential but has not been fully developed.
C-32 triterpene cycloneolitsol or its pharmaceutically acceptable salt as active ingredient is used to prepare drugs that promote the proliferation and differentiation of osteoblasts, and its anti-osteoporosis effect is verified through cell experiments and animal experiments.
cycloneolitsol significantly promotes osteoblast proliferation, reverses the dysfunction of induced osteogenic differentiation, significantly increases the bone density of postmenopausal osteoporosis mice, and is dose-dependent, proving that it is an effective anti-osteoporosis drug component.
Smart Images

Figure CN118924768A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to the application of C-32 triterpene cycloneolitsol in preparing a drug for preventing or treating osteoporosis. Background Art
[0002] With the aging of the population, the world is facing the challenge of metabolic diseases related to aging. Osteoporosis, as a common disease of the elderly, has seriously affected the quality of life of patients. Osteoporosis is a common metabolic bone disease, which is mainly characterized by decreased bone density and bone destruction, which can easily lead to fractures and functional disorders. As a chronic disease associated with aging, osteoporosis has the characteristics of high incidence, high disability rate, high medical expenses, long course of disease, long course of treatment, and low quality of life, and social attention is still insufficient. The latest survey results show that the prevalence of osteoporosis in people over 50 years old in my country is 19.2%, of which the prevalence of men is 6.0% and the prevalence of women is as high as 32.1%. Obviously, osteoporosis has ranked third among chronic diseases and has become another important health problem for the middle-aged and elderly population after diabetes and hypertension. Osteoporosis usually has no symptoms in the early stage, or manifests as fatigue, back discomfort or pain. Typical symptoms often occur after fractures. If the disease is not treated well, the disease will gradually progress, and joint deformity and stiffness may lead to loss of function, which seriously affects the patient's quality of life. At present, modern medicine has no clear treatment for this disease, and it is mainly treated with Western medicine. However, long-term use of Western medicine has a large number of adverse reactions, which affects the patient's treatment outcome and compliance, and the long-term prognosis is average.
[0003] Postmenopausal osteoporosis is a common osteoporosis in postmenopausal women. It is a bone metabolism disease caused by the decline of ovarian function and the decrease of estrogen levels in postmenopausal women, which leads to bone absorption greater than bone formation, low bone mass and degenerative lesions of bone tissue microstructure, and increased bone brittleness. It usually occurs 5 to 10 years after menopause in women, and the incidence rate gradually increases with age. The current Western medicine drugs for the treatment of postmenopausal osteoporosis include bone resorption inhibitors (bisphosphonates, calcitonin), bone formation promoters, estrogen replacement therapy, calcium, vitamin D, etc., but adverse reactions such as gastrointestinal pain and acid reflux may occur after taking them.
[0004] As an important resource of traditional Chinese medicine, traditional Chinese medicine is widely used in the treatment of osteoporosis. Traditional Chinese medicine has unique advantages in the treatment of osteoporosis, such as comprehensive regulation of multiple targets and few adverse reactions, which provides new ideas and methods for the prevention and treatment of osteoporosis by Western medicine, traditional Chinese medicine and the combination of traditional Chinese and Western medicine. Studies have shown that a variety of traditional Chinese medicines have the potential to treat osteoporosis. For example, intervention with Morinda officinalis can improve osteoporosis bone loss and bone strength after ovariectomy, and improve postmenopausal osteoporosis; Achyranthes bidentata can significantly reduce the serum phosphorus and alkaline phosphatase levels in osteoporosis model rats, thereby improving the symptoms of osteoporosis; in addition, traditional Chinese medicines such as Dipsacus asper and Cimicifuga heracleifolia, which are rich in triterpenoid saponins, also have anti-osteoporosis effects.
[0005] Cycloneolitsol (CL) is a cycloaltinane-type triterpene with a structure as shown in Formula Ⅰ. It is a triterpene with a special C-32 structure. This compound is mainly found in the taxodium of the genus Taxodium in the family Taxaceae, the plumbago of the genus Cyperus in the family Orchidaceae, the bletilla of the genus Bletilla in the family Orchidaceae, and the lycopodii of the genus Lithospermum in the family Orchidaceae.
[0006]
[0007] The literature "C-32 triterpenes from Taxodium ascendens" (Biochemical Systematics and Ecology, 2005, 33: 211-214), "NEW TRITERPENOIDS FROM THE ORCHIDSSCAPHYGLOTTIS LIVIDA AND NIDEMABOOTHII" (Natural Product Letters, 2001, 16: 2, 81-86), "Study on the chemical composition of Yunnan Shixiantao" (China Journal of Traditional Chinese Medicine, 2004, 29: 47-49) reported that cycloneolitsol was extracted and isolated from plants such as Pool Cypress, Lead-colored Channel Lip Orchid, Yunnan Shixiantao, etc. There is no report on the anti-osteoporosis effect of cycloneolitsol. Summary of the invention
[0008] In view of this, the purpose of the present invention is to provide a C-32 triterpene cycloneolitsol or a pharmaceutically acceptable salt thereof for use in preparing a drug for preventing or treating osteoporosis, and further, cycloneolitsol or a pharmaceutically acceptable salt thereof for use in preparing a drug for promoting osteoblast proliferation and differentiation, and preparing a drug for treating postmenopausal osteoporosis.
[0009] The present invention provides a use of C-32 triterpene cycloneolitsol or a pharmaceutically acceptable salt thereof having a structure of formula I in the preparation of a drug for preventing or treating osteoporosis:
[0010]
[0011] Furthermore, the drug for treating osteoporosis is a drug that promotes osteoblast proliferation.
[0012] Furthermore, the drug for treating osteoporosis is a drug for treating postmenopausal osteoporosis.
[0013] Furthermore, the medicine also contains pharmaceutically acceptable excipients.
[0014] Furthermore, the pharmaceutically acceptable excipient is one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier and a lubricant.
[0015] Compared with the prior art, the present invention found through cell experiments that C-32 triterpenoid cycloneolitsol can promote the proliferation of osteoblasts, inhibit H2O2-induced cytotoxicity, reverse H2O2-induced osteogenic differentiation dysfunction, and significantly increase ALP activity, indicating that C-32 triterpenoid cycloneolitsol can be used as an active ingredient in anti-osteoporosis drugs. Animal experiments found that C-32 triterpenoid cycloneolitsol can significantly increase the bone density of postmenopausal osteoporotic mice and is dose-dependent, further proving that C-32 triterpenoid cycloneolitsol can be used as an active ingredient in anti-osteoporosis drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 is the hydrogen nuclear magnetic resonance spectrum of cycloneolitsol, a compound of the present invention;
[0017] Figure 2 The carbon spectrum of cycloneolitsol, an example compound of the present invention. DETAILED DESCRIPTION
[0018] To further illustrate the present invention, the use of cycloneolitsol or a pharmaceutically acceptable salt thereof provided by the present invention for preparing a medicament for preventing or treating osteoporosis is described in detail below in conjunction with examples.
[0019] In this example, the compound cycloneolitsol was prepared by extraction, separation and purification from the leaves of Taxodium ascendens according to the method disclosed in the literature "C-32 triterpenes from Taxodium ascendens" (Biochemical Systematics and Ecology, 2005, 33: 211-214). The compound was identified as cycloneolitsol by hydrogen and carbon nuclear magnetic resonance spectra. Figure 1 and Figure 2 .
[0020] Example 1: Effects of cycloneolitsol on proliferation and differentiation of MC3T3-E1 cells
[0021] 1) Cell culture: MC3T3-E1 cells were cultured at 5×10 3 Cells / cm 2 The cells were inoculated at a density of 1.50 μg / mL in a culture flask, and 25 mL of complete culture medium containing 10% fetal bovine serum was added. When the cells were fused to 80% to 90%, the basal culture medium was replaced with osteogenic differentiation induction medium (OM, dexamethasone 0.1 μmol / L, vitamin C 50 mg / L, and β-glycerophosphate 10 mmol / L). The induction medium was replaced every 48 h.
[0022] 2) Cell grouping: Take MC3T3-E1 cells in the logarithmic growth phase and adjust the cell concentration to 1×10 5 / ml were inoculated in 96-well plates. They were divided into blank control group, H2O2 group (0.5mM), H2O2+cycloneolitsol low-dose group (2.5μM CL), H2O2+cycloneolitsol medium-dose group (5μM CL) and H2O2+cycloneolitsol high-dose group (10μM CL). The culture was continued for 72h.
[0023] 3) CCK-8 cell activity assay: Take out the 96-well plate, add 10 μL of CCK-8 solution directly to each well in the dark, and place in a 37°C, 5% CO2 cell culture incubator for 1 hour. Use a multifunctional microplate reader to detect the absorbance value of each well at OD 450nm and calculate the cell survival rate.
[0024] 4) Alkaline phosphatase (ALP) activity assay: MC3T3-E1 cells were treated with 0.5mM H2O2 for 24h, and osteogenic induction solution containing different concentrations of cycloneolitsol was added to induce differentiation for 7 days. After fixing the cells with 4% paraformaldehyde, alkaline phosphatase staining working solution was prepared according to the instructions for staining for 30 minutes, and 70μL of Ripa lysis solution was added to each well to lyse the cells. The supernatant was collected as a sample after centrifugation. The standard and activity assay working solution were prepared according to the instructions. After sufficient oscillation and mixing, 50μL of substrate, 30μL of buffer and 20μL of sample were added to each well of the 96-well plate, with a total volume of 100μL, and 3 replicates were set for each group. Incubate at 37℃ for 15min, and add 100μL of reaction stop solution to each well to terminate the reaction. The absorbance value at 405nm was detected by an enzyme reader; the ALP activity enzyme assay standard curve was drawn according to the absorbance value of the standard provided by the kit, and the specific content of alkaline phosphatase was obtained according to the standard curve. The results are shown in Tables 1 and 2.
[0025] Table 1. Effect of cycloneolitsol on the survival rate of MC3T3-E1 cells ( n=3)
[0026]
[0027]
[0028] Compared with the control group * P<0.05; compared with H2O2 group # P<0.05
[0029] Table 2. Effect of cycloneolitsol on alkaline phosphatase (ALP) activity ( n=3)
[0030]
[0031] Compared with the control group * P<0.05; compared with H2O2 group # P<0.05
[0032] The above experimental results show that the compound cycloneolitsol of the present invention can promote the proliferation of osteoblasts, inhibit the cytotoxicity induced by H2O2, reverse the osteogenic differentiation dysfunction induced by H2O2, and significantly increase the ALP activity, indicating that cycloneolitsol can be used as an active ingredient of anti-osteoporosis drugs.
[0033] Example 2: Effect of cycloneolitsol on bone density in model mice
[0034] The present invention adopts bilateral ovariectomized (OVX) method to establish postmenopausal osteoporosis model in mice. Eight-week-old female C57BL / 6J mice were randomly divided into sham operation group, model group and cycloneolitsol treatment low-dose group (2mg / kg) and high-dose group (10mg / kg), with 6 mice in each group. Sham operation group (cut the skin and peritoneum of mice, expose the ovaries, return to the cavity and re-suture without destroying the peritoneal structure), model group (ovariectomy), low-dose group (cycloneolitsol 2mg / kg administration after ovariectomy) and high-dose group (cycloneolitsol 10mg / kg administration after ovariectomy). After the modeling operation was completed, the mice were given a one-week postoperative recovery period. After one week, the low-dose group and the high-dose group were gavaged with cycloneolitsol every day, and the model group mice were gavaged with the same volume of 0.9% sodium chloride solution for 8 weeks. After the animals were anesthetized, the bone density (BMD) values of the fourth lumbar vertebra and right femur of the rats were measured using a bone densitometer. SPSS 22.0 software was used for analysis of variance and LSD-t test, and the results are shown in Table 3.
[0035] Table 3. Effect of cycloneolitsol on bone mineral density in OVX mice ( n=3)
[0036]
[0037] Compared with the blank group * P<0.05; compared with the model group # P<0.05
[0038] The experimental results showed that compared with the model group, the bone mineral density values of the fourth lumbar vertebra and right femur in the low-dose and high-dose cycloneolitsol groups were significantly increased (P < 0.05), indicating that cycloneolitsol can significantly increase the bone mineral density of postmenopausal osteoporotic mice in a dose-dependent manner and can be used as an active ingredient in anti-osteoporosis drugs.
Claims
1. Use of C-32 triterpene cycloneolitsol or its pharmaceutically acceptable salt having the structure of formula I in the preparation of a drug for preventing or treating osteoporosis:
2. The use according to claim 1, characterized in that: The drug for treating osteoporosis is a drug for promoting the proliferation of osteoblasts.
3. The use according to claim 1, characterized in that: The drug for treating osteoporosis is a drug for treating postmenopausal osteoporosis.
4. The use according to claim 1, characterized in that: The medicine also contains pharmaceutically acceptable excipients.
5. The use according to claim 4, characterized in that: The pharmaceutically acceptable excipients are one or more of diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers and lubricants.
Citation Information
Cited By
Application of CL in preparation of medicine for preventing or treating depression and anxiety
CN119523992A
Use of cl in the preparation of a drug for preventing or treating depression, anxiety
CN119523992B
Application of CL in medicine for treating and preventing Alzheimer's disease and Parkinson's disease
CN119792310A
Application of CL in the treatment and prevention of Alzheimer's disease and Parkinson's disease
CN119792310B
